WFRF:(Lamberts Steven W.J.)
Search: WFRF:(Lamberts Steven W.J.) > (2016) > Somatostatin analog...
- 1 of 1
- Previous record
- Next record
- To hitlist
- Öberg, KjellUppsala universitet,Endokrin tumörbiologi (author)
Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours : past, present and future
- Article/chapterEnglish2016
Publisher, publication year, extent ...
- 2016
- printrdacarrier
Numbers
- LIBRIS-ID:oai:DiVA.org:uu-313614
- https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-313614URI
- https://doi.org/10.1530/ERC-16-0151DOI
Supplementary language notes
- Language:English
- Summary in:English
Part of subdatabase
- SwePubSwePub
Classification
Notes
- Acromegaly is a hormonal disorder that arises when the pituitary gland secretes excess growth hormone (GH), which in turn stimulates a concomitant increase in serum insulin-like growth factor 1 (IGF-1) levels. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) constitute a heterogeneous group of tumours that can secrete serotonin and a variety of peptide hormones that may cause characteristic symptoms known as carcinoid syndrome or other symptoms and hormonal hypersecretion syndromes depending on the tumour's site of origin. Current medical therapy for the treatment of acromegaly and GEP-NET involves the administration of somatostatin analogues that effectively suppress excess hormone secretion. After its discovery in 1979, octreotide became the first synthetic biologically stable somatostatin analogue with a short-acting formulation of octreotide introduced into clinical practice in the late 1980s. Lanreotide, another somatostatin analogue, became available in the mid-1990s initially as a prolonged-release formulation administered every 10 or 14 days. Long-acting release formulations of both octreotide (Sandostatin LAR and Novartis) and lanreotide (Somatuline Autogel, Ipsen), based on microparticle and nanoparticle drug-delivery technologies, respectively, were later developed, which allowed for once-monthly administration and improved convenience. First-generation somatostatin analogues remain one of the cornerstones of medical therapy in the management of pituitary and GEP-NET hormone hypersecretion, with octreotide having the longest established efficacy and safety profile of the somatostatin analogue class. More recently, pasireotide (Signifor), a next-generation multireceptor-targeted somatostatin analogue, has emerged as an alternative therapeutic option for the treatment of acromegaly. This review summarizes the development and clinical success of somatostatin analogues.
Subject headings and genre
- MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Cancer och onkologi hsv//swe
- MEDICAL AND HEALTH SCIENCES Clinical Medicine Cancer and Oncology hsv//eng
- octreotide
- acromegaly
- neuroendocrine
- somatostatin analogue
- GEP-NET
Added entries (persons, corporate bodies, meetings, titles ...)
- Lamberts, Steven W. J.Erasmus MC, Rotterdam, Netherlands. (author)
- Uppsala universitetEndokrin tumörbiologi (creator_code:org_t)
Related titles
- In:Endocrine-Related Cancer23:12, s. R551-R5661351-00881479-6821
Internet link
Find in a library
- Endocrine-Related Cancer (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Öberg, Kjell
- Lamberts, Steven ...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Cancer and Oncol ...
- Articles in the publication
- Endocrine-Relate ...
- By the university
- Uppsala University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
